Florence Casset‐Semanaz

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Thomas Leist, Giancarlo Comi, Bruce Cree et al. · The Lancet Neurology · 2014 · 246 citations

Life Sciences, Neurology, Pharmacotherapy +8

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Nicola De Stefano, Mark S. Freedman, Frederik Barkhof et al. · The Lancet Neurology · 2011 · 214 citations

Life Sciences, Immunology, Neurology +8

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

Ludwig Kappos, Jens Kühle, Juha Multanen et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 84 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis

D Švecová, Martin Lubell, Florence Casset‐Semanaz et al. · Journal of the American Academy of Dermatology · 2019 · 84 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

Gavin Giovannoni, Florence Casset‐Semanaz, Amer Jaber et al. · Clinical Therapeutics · 2007 · 55 citations

Life Sciences, Immunology, Neurology +11